Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Agents capable of reversing P-glycoprotein-associated multidrug resistance have usually failed to enhance chemotherapy activity in patients with solid tumours. Based on its toxicity profile and experimental potency, dexverapamil, the R-enantiomer of verapamil, is considered to be promising for clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehnert, M., Mross, K., Schueller, J., Thuerlimann, B., Kroeger, N., Kupper, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150143/
https://www.ncbi.nlm.nih.gov/pubmed/9569055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150143/
https://www.ncbi.nlm.nih.gov/pubmed/9569055

Ejemplares similares